Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published-Ahead-of-Print July 3, 2008, DOI:10.2164/jandrol.108.005264

This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
29/6/630    most recent
Author Manuscript (PDF)
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurbatov, D.
Right arrow Articles by Traish, A. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurbatov, D.
Right arrow Articles by Traish, A. M

Testosterone Improves Erectile Function in Hypogonadal Patients with Venous Leakage

Dmitry Kurbatov , Jury Kuznetsky , and Abdulmaged M Traish *

* To whom correspondence should be addressed. E-mail: atraish{at}bu.edu.

The goal of this study was to assess the therapeutic benefits of long-acting testosterone therapy in hypogonadal patients with erectile dysfunction (ED). We recruited 29 patients with ED ranging in age from 32 - 65 years (47 ± 9.7) with low plasma testosterone, who did not respond to phosphodiesterase type 5 (PDE-5) inhibitors therapy. To evaluate penile arterial and venous blood flow, we employed Duplex Doppler Ultrasonography (DDU). For confirmation of diagnosis of venous leakage, pharmaco-cavernosography (PCG) was carried out in 9 patients and Magnetic Resonance Imaging (MRI) with intracavernous contrast enhancement was carried out in 8 patients. All patients were treated with 1000 mg injectable testosterone undecanoate on day one, followed by another injection after six weeks and every three months thereafter, in accordance with Nebido therapy protocol. Plasma testosterone levels were determined in all patients at baseline and after 12 and 30 weeks of testosterone treatment. The International Index of Erectile Function (IIEF-5) was administered at base line, and after 12 and 30 weeks of testosterone treatment. At base line total testosterone ranged from 7-11.8 nmol/l (200-345 ng/dl) in all patients. Twelve and 30 weeks after testosterone treatment, the mean testosterone plasma levels were 18 and 21.5 nmol/l (520 and 625 ng/dl), respectively. After twelve and 30 weeks of testosterone treatment, 20 out of the 29 patients demonstrated marked improvement in erectile function domain, as assessed by IIEF-5. This was also associated with diminution of venous leakage. We suggest that, in hypogonadal men with ED, testosterone therapy improves erectile function in patients with ED and venous leakage.


Key words: Androgen • Erectile Dysfunction • Hormone • Penis • Hypogonadism • Long-acting Testosterone • Magnatic Imaging Resonance • Testosterone • Venous Leakage




This article has been cited by other articles:


Home page
 J AndrolHome page
A. M. Traish
Androgens Play a Pivotal Role in Maintaining Penile Tissue Architecture and Erection: A Review
J Androl, July 1, 2009; 30(4): 363 - 369.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by The American Society of Andrology.